Cargando…

Impact of ‘4+7’ volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China

OBJECTIVE: To evaluate the impact of the first round of the National Centralized Drug Procurement pilot (so-called ‘4+7’ policy) on the use of policy-related original and generic drugs. METHODS: A retrospective natural experimental design was adopted. Drug procurement data from the China Drug Supply...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Yang, Ying, Xu, Luxinyi, Shen, Yuan, Wen, Xiaotong, Mao, Lining, Wang, Quan, Cui, Dan, Mao, Zongfu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Health Policy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921850/ https://www.ncbi.nlm.nih.gov/pubmed/35288385 http://dx.doi.org/10.1136/bmjopen-2021-054346

Ejemplares similares

Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis
por: Wang, Ni, et al.
Publicado: (2021)

The impact of “4 + 7” volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis
por: Yang, Ying, et al.
Publicado: (2021)

A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China
por: Wen, Xiaotong, et al.
Publicado: (2023)

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
por: Yang, Ying, et al.
Publicado: (2021)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
por: Wen, Xiaotong, et al.
Publicado: (2022)

The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China
por: Chen, Lei, et al.
Publicado: (2020)

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China
por: Lu, Jiancheng, et al.
Publicado: (2022)

Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study
por: Wang, Xiaoyang, et al.
Publicado: (2023)

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Reevaluation of adverse drug reactions of psychiatric drugs under the chinese drug volume-based procurement policy
por: Du, Zhiqiang, et al.
Publicado: (2022)

Generic drugs: Review and experiences from South India
por: Mathew, Philip
Publicado: (2015)

Understanding public drug procurement in India: a comparative qualitative study of five Indian states
por: Singh, Prabal Vikram, et al.
Publicado: (2013)

The Role of Funding and Policies on Innovation in Cancer Drug Development
por: Kanavos, P, et al.
Publicado: (2010)

Paying Physicians to Prescribe Generic Drugs and Follow-On Biologics in the United States
por: Sarpatwari, Ameet, et al.
Publicado: (2015)

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

European collaborations on medicine and vaccine procurement
por: Vogler, Sabine, et al.
Publicado: (2021)

The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis
por: Wang, Xiao, et al.
Publicado: (2023)

Drug procurement, the Global Fund and misguided competition policies
por: Tren, Richard, et al.
Publicado: (2009)

Antibiotic Use in China’s Public Healthcare Institutions During the COVID-19 Pandemic: An Analysis of Nationwide Procurement Data, 2018–2020
por: Yang, Ying, et al.
Publicado: (2022)

Improving access to medicines and beyond: the national volume-based procurement policy in China
por: Zhu, Zheng, et al.
Publicado: (2023)

Impact of China’s National Centralized Drug Procurement Policy on pharmaceutical enterprises’ financial performance: a quasi-natural experimental study
por: Sun, Zhixuan, et al.
Publicado: (2023)

A National Cancer Grid pooled procurement initiative, India
por: Pramesh, C S, et al.
Publicado: (2023)

The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need
por: Dionne, Pierre-Alexandre, et al.
Publicado: (2016)

Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls
por: Chen, Yilin, et al.
Publicado: (2021)

The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis
por: Wen, Xiaotong, et al.
Publicado: (2021)

Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
por: Yi, Hongbin, et al.
Publicado: (2023)

Reshaping Australian drug policy: the dilemmas of generic medicines policy
por: Löfgren, Hans
Publicado: (2007)

Awareness of the role of general practitioners in primary care among outpatient populations: evidence from a cross-sectional survey of tertiary hospitals in China
por: Liu, Xiaojun, et al.
Publicado: (2018)

Phosphoethanolamine and the danger of unproven drugs
por: Pondé, Noam, et al.
Publicado: (2016)

Telerehabilitation Policy Report: Interprofessional Policy Principles and Priorities
por: Terrell, Evelyn Abrahante, et al.
Publicado: (2021)

US Organ Procurement Organization Donation Principles, Laws, and Practices
por: Mone, Thomas, et al.
Publicado: (2020)

Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016
por: ‘t Hoen, Ellen FM, et al.
Publicado: (2018)

Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016–2018: an interrupted time series study in Shaanxi
por: Yan, Kangkang, et al.
Publicado: (2020)

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
por: Kesselheim, Aaron S., et al.
Publicado: (2017)

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
por: Zhao, Xinyu, et al.
Publicado: (2022)

The Repurposing Drugs in Oncology (ReDO) Project
por: Pantziarka, Pan, et al.
Publicado: (2014)

Policy on Ford Foundation
Publicado: (1956)

Policy change and policy dilemmas: interpreting the community services White Paper in England
por: Hudson, Bob
Publicado: (2006)

RELATIONSHIP BETWEEN FINANCIAL IMPACT AND COVERAGE OF DRUGS IN AUSTRALIA
por: Mauskopf, Josephine, et al.
Publicado: (2013)

Will Spam Overwhelm Our Defenses? Evaluating Offerings for Drugs and Natural Health Products
por: Gernburd, Peter, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_osocfe91u5tiprcdatcdns6cvm